Percutaneous coronary intervention in elderly patients: Is It Beneficial?

Texas Heart Institute Journal

Volumn 38, Issue 4, 2011, Pages 398-403

  Shanmugasundaram, Madhan ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Age factors; Angina; Attitude of health personnel; Cardiovascular diseases complications mortality prevention; Control therapy; Health services for the aged standards; Heart catheterization utilization; Myocardial revascularization utilization; randomized controlled trialsas topic statistics; Numericaldata; Risk factors; Survival analysis; Treatment outcome; Unstable complications prevention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

AGING; ARTERY CATHETERIZATION; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; HEART DISEASES; HUMANS; MYOCARDIAL INFARCTION; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 80051754071     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Kinsella K. Urban and rural dimensions of global population aging: an overview. J Rural Health 2001;17(4):314-22.
2. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80(7):1273-83.
3. Kochanek KD, Smith BL. Deaths: preliminary data for 2002. Natl Vital Stat Rep 2004;52(13):1-47.
4. Wennberg DE, Makenka DJ, Sengupta A, Lucas FL, Vaitkus PT, Quinton H, et al. Percutaneous transluminal coronary angioplasty in the elderly: epidemiology, clinical risk factors, and in-hospital outcomes. The Northern New England Cardiovascular Disease Study Group. Am Heart J 1999;137(4 Pt 1):639-45.
5. Rathore SS, Mehta RH, Wang Y, Radford MJ, Krumholz HM. Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med 2003;114 (4):307-15.
6. Sheifer SE, Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Breall JA, Schulman KA. Time to presentation with acute myocardial infarction in the elderly: associations with race, sex, and socioeconomic characteristics. Circulation 2000;102 (14):1651-6.
7. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992;268(11):1417-22.
8. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995;91(6):1659-68.
9. Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. JAMA 1995;273(20): 1586-91.
10. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328(10):673-9.
11. Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol 1995;25(2):370-7.
12. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators [published erratum appears in N Engl J Med 1997;337(4):287]. N Engl J Med 1997;336(23): 1621-8.
13. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349(8):733-42.
14. Goldenberg I, Matetzky S, Halkin A, Roth A, Di Segni E, Freimark D, et al. Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J 2003;145(5):862-7.
15. de Boer MJ, Ottervanger JP, van 't Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;39(11):1723-8.
16. Senior PAMI: Primary angioplasty versus thrombolytic therapy for acute myocardial infarction in the elderly [Internet; updated 2005 Dec 12; cited 2011 Jul 14]. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00136929.
17. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ; PCAT Collaborators. Percutaneous transluminal coronary angioplasty. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003;145(1):47-57.
18. Anderson HV, Cannon CP, Stone PH, Williams DO, Mc-Cabe CH, Knatterud GL, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction [published erratum appears in J Am Coll Cardiol 2000;35(1):263]. J Am Coll Cardiol 1995;26(7):1643-50.
19. Long-term low-molecular-mass heparin in unstable coronaryartery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators [published erratum appears in Lancet 1999;354(9188):1478]. Lancet 1999;354 (9180):701-7.
20. Lagerqvist B, Husted S, Kontny F, Naslund U, Stahle E, Swahn E, et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol 2002;40(11):1902-14.
21. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344(25):1879-87.
22. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004;141(3):186-95.
23. de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005;353(11):1095-104.
24. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004;292(17):2096-104.
25. Singh M, Peterson ED, Roe MT, Ou FS, Spertus JA, Rumsfeld JS, et al. Trends in the association between age and inhospital mortality after percutaneous coronary intervention: National Cardiovascular Data Registry experience. Circ Cardiovasc Interv 2009;2(1):20-6.
26. Dzavik V, Sleeper LA, Picard MH, Sanborn TA, Lowe AM, Gin K, et al. Outcome of patients aged >or=75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? Am Heart J 2005;149(6):1128-34.
27. Dauerman HL, Ryan TJ Jr, Piper WD, Kellett MA, Shubrooks SJ, Robb JF, et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol 2003; 15(7):380-4.
28. Dauerman HL, Goldberg RJ, Malinski M, Yarzebski J, Lessard D, Gore JM. Outcomes and early revascularization for patients > or = 65 years of age with cardiogenic shock. Am J Cardiol 2001;87(7):844-8.
29. Berger AK, Radford MJ, Krumholz HM. Cardiogenic shock complicating acute myocardial infarction in elderly patients: does admission to a tertiary center improve survival? Am Heart J 2002;143(5):768-76.
30. TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001;358(9286): 951-7.
31. Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003;289(9):1117-23.
32. Pfisterer M; Trial of Invasive versus Medical therapy in Elderly patients Investigators. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation 2004;110(10):1213-8.
33. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration [published erratum appears in BMJ 1994;308(6943):1540]. BMJ 1994; 308(6921):81-106.
34. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation [published errata appear in N Engl J Med 2001;345(20):1506 and N Engl J Med 2001;345(23):1716]. N Engl J Med 2001;345(7):494-502.
35. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33.
36. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339(7):436-43.
37. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial [published erratum appears in JAMA 2006;296(1):46]. JAMA 2004; 292(6):696-703.
38. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355(10):1006-17.